ICD-10-CM Billable Code

M11.161

Familial chondrocalcinosis, right knee

Clinical Classification Guidelines

Medical Intelligence & Overview

Familial chondrocalcinosis, also known as calcium pyrophosphate deposition disease (CPPD), is a condition characterized by the buildup of calcium pyrophosphate crystals in the cartilage of joints, leading to joint inflammation and degeneration. When this condition specifically affects the right knee, it is classified under ICD-10 code M11.161. This condition often runs in families, suggesting a genetic predisposition, and presents with a variety of symptoms related to joint discomfort and swelling.

Causes & Symptoms

Clinical Causes: Genetic Factors: A family history of chondrocalcinosis increases the likelihood of developing the condition. Metabolic Disorders: Conditions such as hyperparathyroidism, hemochromatosis, or hypophosphatasia can contribute to crystal formation. Aging: The risk of crystal deposition increases with age due to changes in joint cartilage. Joint Injury: Previous trauma or cartilage damage can predispose the joint to crystal accumulation. Environmental Factors: Dietary habits and other environmental influences may also play a role.

Key Symptoms: Joint Pain: Often sudden and severe pain episodes, especially during flare-ups. Swelling: The affected joint may become swollen and tender to touch. Reduced Mobility: Difficulty moving the involved joint, leading to stiffness. Warmth and Redness: The joint may appear inflamed with warmth and redness. Recurring Attacks: Symptoms tend to recur, often affecting the same joint.

Diagnostic & Treatment

Diagnosis Path: Diagnosis typically involves a combination of clinical evaluation and diagnostic tests. Key steps include: - Medical History Review: Emphasis on family history and past joint issues. - Physical Examination: Assessing swelling, tenderness, and range of motion. - Imaging Tests: X-rays can reveal calcifications within the cartilage indicative of chondrocalcinosis. - Joint Fluid Analysis: Extracted synovial fluid under a microscope can confirm the presence of calcium pyrophosphate crystals. - Blood Tests: To identify underlying metabolic conditions that may contribute to crystal formation.

Treatment Protocols: Treatment aims to manage symptoms and prevent joint damage. Common approaches include: - Medications: - Nonsteroidal anti-inflammatory drugs (NSAIDs): To reduce pain and inflammation. - Colchicine: Useful during acute attacks and for flare prevention. - Corticosteroids: Injections or oral steroids for severe inflammation. - Lifestyle and Supportive Measures: - Resting the affected joint during flare-ups. - Applying ice packs to reduce swelling. - Engaging in low-impact exercises to maintain joint function. - Weight management to alleviate joint stress. - Managing Underlying Conditions: - Treating metabolic disorders such as hyperparathyroidism or hemochromatosis. - Dietary adjustments to avoid triggers and support joint health. - Surgical Options: - In advanced cases, procedures like joint replacement may be considered if pain and mobility issues are severe.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is M11.161 a billable ICD-10 code?
Yes, M11.161 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report M11.161?
Clinical documentation must specify the nature of Familial chondrocalcinosis, right knee and any associated comorbidities for accurate reporting.

Cite this Clinical Reference